Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?
In an article published in the current issue of anti cancer research journal, Professor Mokbel and his team from the London Breast Institute have investigated weather adjuvant Tamoxifen therapy is indicated in women who had complete surgical excision of estrogen receptor (ER) positive ductal carcinoma in situ (DCIS) which is a non-invasive form of breast cancer. After analysing the quality of evidence and benefit risk balance, the authors have concluded that tamoxifen is not indicated if the tumour is completely excised and the patient receives radiation therapy after lumpectomy.
Professor Mokbel highlighted that there was no evidence that tamoxifen improved overall survival or decreased the chances of getting invasive breast cancer in the same breast. On the other hand the drug is associated with significant adverse effects that could compromise the quality of life and is rarely associated with serious side-effects such as cancer of the womb or developing blood clots. However, the drug can be used in a subgroup of young women who have an aggressive form of the disease. Tamoxifen also has a role as a chemoprevention drug in women who are at an increased risk. Again in this context there is no evidence that it improves survival.
The article was awarded an exceptional quality status by the journal.